Conferences - Results from #9700

Viewing 9701-9720 of 11300 articles

ASCO GU 2016 State of Predictive Biomarkers and Response to Immunotherapy in Advanced Disease - Session Highlights

ASCO GU 2016 Urothelial Carcinomas: Year in Review - Session Highlights

ASCO GU 2016 Novel Checkpoint Blockade Strategies in Non-Muscle Invasive Bladder Cancer: Urologist Perspective - Session Highlights

ASCO GU 2016 Abstract 355: IMvigor 210, a phase 2 trial of atezolizumab (MPDL3280A) in platinum-treated locally advanced or metastatic urothelial carcinoma - Session Highlights

ASCO GU 2016 Best of Journals: Prostate Cancer Medical Oncology - Session Highlights

ASCO GU 2016 Best of Journals: Prostate Cancer Surgical Oncology - Session Highlights

ASCO GU 2016 Best of Journals: Prostate Cancer Radiation Oncology - Session Highlights

ASCO GU 2016 Changes in the Treatment of Hormone-Naïve Metastatic Prostate Cancer - Session Highlights

ASCO GU 2016 Evaluating PSA nadir drift in high-risk and metastatic prostate cancer. - Poster Session Highlights

ASCO GU 2016 Prostate Cancer: Year in Review - Session Highlights

ASCO GU 2016 Best Use of Approved Therapies for Bone Metastases - Session Highlights

ASCO GU 2016 Open-label phase II study evaluating the efficacy of concurrent administration of radium Ra 223 dichloride (Ra-223) and abiraterone acetate (AA) in men with castration-resistant prostate cancer (CRPC) patients with symptomatic bone metastases

ASCO GU 2016 – Oral Abstract Session: NRG Oncology/RTOG 9601, a phase III trial in prostate cancer patients: Anti-androgen therapy (AAT) with bicalutamide during and after salvage radiation therapy (RT) following (RP) and an elevated PSA. - Session Highl

ASCO GU 2016 Celecoxib with or without zoledronic acid for hormone-naïve prostate cancer: Survival results from STAMPEDE (NCT00268476). – Poster Session Highlights

ASCO GU 2016 Comparison of hypofractionated high-dose intensity-modulated radiotherapy schedules for prostate cancer: Results from the phase III randomized CHHiP trial. – Session Highlights

ASCO GU 2016 Changes in T cell immunity in patients with metastatic castration resistant prostate treated with Radium-223 treatment. – Poster Session Highlights

ASCO GU 2016 Cardiovascular events in prostate cancer patients: A comparative analysis of German claims data. - Poster Session Highlights

ASCO GU 2016 ODM-204, a novel dual inhibitor of CYP17A1 and androgen receptor for the treatment of castration-resistant prostate cancer. - Poster Session Highlights

ASCO GU 2016 Novel Targets for Castrate-Resistant Prostate Cancer - Session Highlights

ASCO GU 2016 Effects of PSA screening guidelines on trends of diagnosis and treatment for prostate cancer: Analysis from the National Cancer Data Base (NCDB). - Poster Session Highlights

481
482
483
484
485
486
487
488
489
490